Adlai Nortye (NASDAQ:ANL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing [Yahoo! Finance]
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Morning Market Pulse: Defense-to-Data Bets, Capital Raises, and AI-Powered Platforms Shape the Open